<DOC>
	<DOCNO>NCT00873912</DOCNO>
	<brief_summary>This prospective annual release study design ass safety monovalent influenza virus vaccine use new strain recommend 2009-2010 influenza season previously contain trivalent intranasal FluMist vaccine . Three hundred healthy adult receive single dose vaccine placebo follow 180 day .</brief_summary>
	<brief_title>A Prospective Study Evaluate Safety New Monovalent Intranasal Influenza Vaccine</brief_title>
	<detailed_description>This prospective , randomize , double-blind , placebo-controlled release study enrol 300 healthy adult 18 49 year age . Eligible participant randomly assign 4:1 fashion receive single dose monovalent vaccine placebo intranasal spray . This study conduct multiple site United States . Randomization stratify site . Each participant receive one dose investigational product Day 1 . The duration study participation participant time receipt investigational product 180 day receipt investigational product .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female , 18 49 year age ( yet reach 50th birthday ) time investigational product administration Healthy medical history physical exam Written inform consent locally require authorization ( eg , Health Insurance Portability Accountability Act [ HIPAA ] United States America [ USA ] , European Union [ EU ] Data Privacy Directive EU ) obtain subject/legal representative prior performing protocolrelated procedure , include screen evaluation Females childbearing potential , unless surgically sterile ( ie , bilateral tubal ligation , bilateral oophorectomy , complete hysterectomy ) , sterile male partner , premenarchal least 2 year postmenopausal , practice abstinence , must use 2 effective method avoid pregnancy ( include oral , transdermal , implanted contraceptive , intrauterine device , female condom spermicide , diaphragm spermicide , cervical cap , use condom spermicide sexual partner ) least 30 day prior dose investigational product , must agree continue use precaution least 90 day dose investigational product ; cessation birth control point discuss responsible physician . The subject must also negative serum urine pregnancy test within 14 day prior investigational product administration ( screen administration investigational product occur day ) day investigational product administration prior randomization Males , unless surgically sterile , must use 2 effective method birth control female partner must agree continue use contraceptive precaution least 30 day dose investigational product ( Day 1 Day 31 study ) Subject available telephone Ability understand comply requirement protocol , judge investigator Ability complete followup period 180 day dose required protocol History hypersensitivity component vaccine , include egg egg protein serious , lifethreatening , severe reaction previous influenza vaccination History hypersensitivity gentamicin Any condition inactivate influenza vaccine indicate , include chronic disorder pulmonary cardiovascular system ( eg , asthma ) , chronic metabolic disease ( eg , diabetes mellitus ) , renal dysfunction , hemoglobinopathy require regular medical followup hospitalization precede year Acute febrile ( &gt; 100.0°F oral equivalent ) and/or clinically significant respiratory illness ( eg , cough sore throat ) within 14 day prior randomization Any known immunosuppressive condition immune deficiency disease , include human immunodeficiency virus [ HIV ] infection , ongoing immunosuppressive therapy History GuillainBarré syndrome A household contact severely immunocompromised ( eg , hematopoietic stem cell transplant recipient , period immunocompromised individual require care protective environment ) ; subject additionally avoid close contact severely immunocompromised individual least 21 day receipt investigational product Receipt investigational agent within 30 day prior randomization , expect receipt 30 day dose investigational product ( use license agent indication list package insert permit ) Expected receipt antipyretic analgesic medication daily every day basis randomization 14 day receipt investigational product Administration intranasal medication within 14 day prior randomization , expect receipt 14 day administration investigational product Known suspect mitochondrial encephalomyopathy Nursing mother Any condition ( eg , chronic cough , allergic rhinitis ) , opinion investigator , would interfere evaluation investigational product interpretation subject safety study result Employees clinical study site individual involve conduct study , immediate family member individual</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>influenza</keyword>
	<keyword>FluMist</keyword>
</DOC>